期刊文献+

过继免疫治疗对手术后肺癌患者T细胞及其活化抗原表达影响的研究 被引量:1

Effects of adoptive immunotheropy on the T cell immunophenotype and activation antigen expression in patients with lung cancer
下载PDF
导出
摘要 目的探讨CIK过继免疫治疗对手术后肺癌患者T细胞及其活化抗原表达的影响。方法采用流式细胞术检测40例肺癌患者外周血T细胞表型CD3、CD4、CD8和及其活化抗原标志CD69、CD25、HLA-DR。结果肺癌患者CD3+、CD4+、CD4/CD8比值明显低于对照组并呈显著性差异,而CD8+细胞高于对照组(P<0.01);肺癌患者CD69、CD3+/HLA-DR+、CD4+/CD25+与对照组比较无显著性差异。经CIK治疗后CD3+、CD4+、CD4/CD8比值都升高,其中CD4+细胞与治疗前比较呈显著性差异(P<0.05),而CD8+细胞与治疗前比较降低(P<0.05);CD69、CD3+/HLA-DR+均升高(P<0.05),CD4+/CD25+在治疗后有增高趋势,但无显著性差异。结论CIK过继免疫治疗对肺癌患者免疫功能的恢复具有促进作用。 Objective To investigate the T cell immunophenotype and activation antigen expression in patients with lung cancer treated with CIK.Methods The T cell subsets and CD69,HLA-DR, CD25 on peripheral blood from patients with lung cancer( n = 40)were detected with flow cytometry.Results The CD3^+ , CD4^+ and CD4/CD8 from pre-operation patients with lung cancer are significantly lower than that of the control( P 〈 0.01 ). Comparied with the control group, the CD8^+ cells from patients with lung cancer were increased( P 〈 0.01). The CD3^+ , CD4^+ and CD4/CD8 from post-operation patients treated with CIK were increased. Comparied with pre-operation, the difference of CD4^+cells is significant( P 〈 0.05) and the CD8^+ ceils were docreased( P 〈 0.05), CD69,CD3^+/HLA - DR ^+ were increased ( P 〈 0.05 ). Conclusion The immunological function of patients with lung cancer were decreased and could be enhanced by CIK adoptive immunotheropy.
出处 《中国实验诊断学》 2006年第5期455-457,共3页 Chinese Journal of Laboratory Diagnosis
基金 吉林省科技厅科研项目(200564) 吉林省科技厅重点科研项目(20040414) 吉林省科技厅重点项目(编号:20040401-5) 吉林省科技厅国际合作项目(编号:20040707-2) 2004年长春市科技局计划项目(编号:2004218)
关键词 过继免疫治疗 CIK 肺癌 CD adoptive immunotheropy CIK lung cancer CD
  • 相关文献

参考文献8

  • 1陈慰峰.医学免疫学[M].北京:人民卫生出版社,2002.197.
  • 2Sheu BC,Hsu SM,Ho HN,et al.Reversed CD4/CD8 ratios of tumorinfiltrating lymphocytes are correlated with the progression of human cervical carcinoma[J].Cancer,1999,86(8):1537.
  • 3Robinson E,Segal R,Struminger L,et al.Lymphocyte Subpopulllations in Patients with Multiple Primary Tumor[J].Cancer,1999,85:2073.
  • 4Yacyshyn MB,Poppema S,Berg A,et al.CD69 + and HLA-DR + activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients:correlations with survival following active specific immunotherapy[J].Int J cancer,1995,61 (4):470.
  • 5Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor-chain(CD25)J].J Immunol,1995,155:1151.
  • 6Mehta BA,Schmidt-Wolf IG,Negrin RS,et al.Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells[J].Blood,1995,86(9):3493.
  • 7Hernberg W,Muhonen T,Turunen JP,et al.The CD4/CD8 ratio as a prognostic favor in patients with metastatic mclanoma receiving chemoimmunotherapy[J].J of Clinical Oncology,1996,14(5):1690.
  • 8Schmidt-Wolf GH,Negrin R S,Kiem H P et al.Use of SCID mouse/human lymphoma model to evaluate cytokine induced killer cells with potent anti-tumor cell activity[J].J Exp Med,1991,174:139.

共引文献38

同被引文献10

  • 1Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004[J]. CA Cancer J Clin.2004, 54 (1):8-29.
  • 2FA S. Chemotherapy for non-small cell lung cancer: have we reached a new plateau[J]. Semin Oncol,1999. 26(Suppl 4):3-11.
  • 3Leemhuis T, Wells S, Scheffold C,et al. A phase Ⅰ trial of autotogous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma[J]. Biol Blood Marrow Transplant, 2005, 11 (3):181-187.
  • 4Jiang J, Xu N, Wu C, Deng H, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells[J]. Anticancer Res,2006, 26 (3B):2237-2242.
  • 5Gritzapis AD, Dimitroulopoulos D, Paraskevas E, et al. Large-scale expansion of CD3 (+)CD56 (+) lymphocytes capable of lysing autologous tumor cells with cytokinerich supernatants[J].Cancer Immunol Immunother,2002, 51 (8):440-448.
  • 6Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paelitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Ontology Group trial[J]. J Clin Oncol,2000, 18 (3):623-631.
  • 7Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase Ⅲ study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol,1999,17(1):12-18.
  • 8Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity[J]. J Exp Med,1991,174(1):139-149.
  • 9Verneris MR, Kornacher M, Mailander V, et al. Resistanee of exvivo expanded CD3^+CD56^+T cells to Fas-mediated appotosis[J]. Cancer immunol immunother, 2000, 49(6):335-345.
  • 10Schmidt-Wolf IG, Leflerova P, Johnston V, et al. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells[J]. Cell Immunol,1996,169(1):85-90.

引证文献1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部